| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 7 | 2021 | 284 | 2.92 | Why? |
| Hemophilia A | 13 | 2021 | 362 | 2.76 | Why? |
| von Willebrand Diseases | 4 | 2019 | 81 | 2.68 | Why? |
| ADAMTS13 Protein | 7 | 2020 | 363 | 2.63 | Why? |
| von Willebrand Factor | 5 | 2020 | 668 | 1.71 | Why? |
| Factor VIII | 9 | 2021 | 229 | 1.67 | Why? |
| Complement Activation | 3 | 2021 | 949 | 1.17 | Why? |
| Antibodies, Bispecific | 4 | 2021 | 207 | 1.16 | Why? |
| Blood Coagulation | 9 | 2021 | 2768 | 1.11 | Why? |
| Coagulants | 2 | 2018 | 30 | 0.94 | Why? |
| Blood Coagulation Disorders, Inherited | 2 | 2021 | 82 | 0.90 | Why? |
| Hemostatics | 2 | 2021 | 142 | 0.83 | Why? |
| Coagulation Protein Disorders | 1 | 2018 | 1 | 0.80 | Why? |
| Purpura, Thrombocytopenic | 1 | 2019 | 12 | 0.79 | Why? |
| Atypical Hemolytic Uremic Syndrome | 1 | 2019 | 62 | 0.75 | Why? |
| Afibrinogenemia | 1 | 2017 | 10 | 0.73 | Why? |
| Blood Chemical Analysis | 2 | 2021 | 541 | 0.73 | Why? |
| Portal Vein | 1 | 2020 | 193 | 0.70 | Why? |
| Thrombosis | 4 | 2021 | 7504 | 0.70 | Why? |
| Mutation, Missense | 5 | 2017 | 863 | 0.68 | Why? |
| Cerebral Veins | 1 | 2018 | 81 | 0.67 | Why? |
| Blood Coagulation Tests | 3 | 2019 | 855 | 0.66 | Why? |
| Hemostasis | 3 | 2021 | 811 | 0.65 | Why? |
| DNA Mutational Analysis | 2 | 2019 | 581 | 0.64 | Why? |
| ADAM Proteins | 2 | 2012 | 43 | 0.62 | Why? |
| Blood Loss, Surgical | 1 | 2017 | 211 | 0.61 | Why? |
| Vitamin K | 1 | 2018 | 263 | 0.59 | Why? |
| Rare Diseases | 1 | 2018 | 373 | 0.56 | Why? |
| Secondary Prevention | 2 | 2019 | 762 | 0.55 | Why? |
| Intracranial Thrombosis | 2 | 2018 | 339 | 0.54 | Why? |
| Rivaroxaban | 1 | 2018 | 467 | 0.53 | Why? |
| Arthroplasty, Replacement, Hip | 1 | 2019 | 403 | 0.51 | Why? |
| Antibodies, Antiphospholipid | 1 | 2018 | 519 | 0.50 | Why? |
| Isoantibodies | 3 | 2019 | 134 | 0.49 | Why? |
| Plasma Exchange | 1 | 2019 | 763 | 0.46 | Why? |
| Hemorrhage | 3 | 2019 | 3013 | 0.46 | Why? |
| Fibrinogen | 1 | 2017 | 1048 | 0.46 | Why? |
| Pre-Exposure Prophylaxis | 1 | 2021 | 1138 | 0.45 | Why? |
| Factor X Deficiency | 3 | 2017 | 17 | 0.45 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2021 | 1731 | 0.44 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2021 | 1261 | 0.44 | Why? |
| Ticlopidine | 1 | 2012 | 193 | 0.44 | Why? |
| Factor X | 2 | 2017 | 18 | 0.43 | Why? |
| Venous Thrombosis | 3 | 2021 | 2739 | 0.42 | Why? |
| Blood Platelets | 2 | 2021 | 1704 | 0.41 | Why? |
| Factor V Deficiency | 2 | 2019 | 30 | 0.40 | Why? |
| Quality of Life | 3 | 2019 | 9820 | 0.38 | Why? |
| Endothelium, Vascular | 1 | 2020 | 1751 | 0.38 | Why? |
| Recurrence | 6 | 2021 | 3675 | 0.38 | Why? |
| Chromosomes, Human, Pair 3 | 2 | 2021 | 195 | 0.37 | Why? |
| Anticoagulants | 3 | 2020 | 9563 | 0.37 | Why? |
| Blood Coagulation Factor Inhibitors | 2 | 2018 | 41 | 0.36 | Why? |
| Prothrombin Time | 3 | 2018 | 434 | 0.35 | Why? |
| Thrombin | 3 | 2019 | 325 | 0.34 | Why? |
| Lupus Erythematosus, Systemic | 1 | 2018 | 1380 | 0.34 | Why? |
| ABO Blood-Group System | 3 | 2021 | 995 | 0.32 | Why? |
| Biomarkers | 7 | 2021 | 23361 | 0.31 | Why? |
| Mutation | 5 | 2019 | 12376 | 0.30 | Why? |
| Antibodies, Monoclonal, Humanized | 4 | 2021 | 9335 | 0.29 | Why? |
| Polypharmacy | 2 | 2018 | 347 | 0.29 | Why? |
| Gene Frequency | 3 | 2021 | 1210 | 0.28 | Why? |
| Genetic Predisposition to Disease | 5 | 2021 | 4027 | 0.28 | Why? |
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2012 | 645 | 0.27 | Why? |
| Elective Surgical Procedures | 2 | 2019 | 5338 | 0.27 | Why? |
| Humans | 71 | 2021 | 930598 | 0.26 | Why? |
| Factor V | 3 | 2019 | 52 | 0.26 | Why? |
| Thrombelastography | 2 | 2020 | 627 | 0.26 | Why? |
| Immunoassay | 1 | 2019 | 4485 | 0.26 | Why? |
| Enoxaparin | 2 | 2021 | 1064 | 0.25 | Why? |
| Linkage Disequilibrium | 2 | 2018 | 191 | 0.25 | Why? |
| Multigene Family | 2 | 2021 | 377 | 0.25 | Why? |
| Ultrasonography, Doppler, Duplex | 2 | 2021 | 168 | 0.24 | Why? |
| Complement C5a | 2 | 2021 | 116 | 0.24 | Why? |
| Platelet Function Tests | 2 | 2021 | 231 | 0.24 | Why? |
| Vaccines | 1 | 2021 | 3692 | 0.24 | Why? |
| Platelet Aggregation Inhibitors | 1 | 2012 | 1671 | 0.23 | Why? |
| Female | 35 | 2021 | 380317 | 0.23 | Why? |
| RNA Splicing | 2 | 2019 | 119 | 0.22 | Why? |
| Male | 36 | 2021 | 367725 | 0.21 | Why? |
| Pulmonary Embolism | 1 | 2020 | 4775 | 0.21 | Why? |
| Immunosuppressive Agents | 1 | 2019 | 6331 | 0.21 | Why? |
| Critical Illness | 3 | 2020 | 17281 | 0.20 | Why? |
| Middle Aged | 24 | 2021 | 270681 | 0.20 | Why? |
| Receptors, Interleukin-1 | 1 | 2020 | 161 | 0.19 | Why? |
| Complement Membrane Attack Complex | 1 | 2020 | 153 | 0.19 | Why? |
| Polymorphism, Single Nucleotide | 4 | 2021 | 3607 | 0.19 | Why? |
| Hypertension | 1 | 2021 | 8895 | 0.19 | Why? |
| Porphyria, Variegate | 1 | 2018 | 1 | 0.19 | Why? |
| Thrombin Time | 1 | 2018 | 46 | 0.19 | Why? |
| Anti-Infective Agents, Urinary | 1 | 2018 | 27 | 0.18 | Why? |
| Factor XI | 1 | 2017 | 3 | 0.18 | Why? |
| Factor XI Deficiency | 1 | 2017 | 7 | 0.18 | Why? |
| Memory Disorders | 1 | 2019 | 190 | 0.18 | Why? |
| INDEL Mutation | 1 | 2018 | 128 | 0.17 | Why? |
| Zebrafish Proteins | 1 | 2017 | 37 | 0.17 | Why? |
| Alleles | 3 | 2019 | 1557 | 0.17 | Why? |
| Adult | 18 | 2021 | 244371 | 0.17 | Why? |
| Energy Metabolism | 1 | 2021 | 451 | 0.16 | Why? |
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2018 | 170 | 0.16 | Why? |
| Aged | 20 | 2021 | 215776 | 0.16 | Why? |
| Blood Coagulation Factors | 1 | 2018 | 223 | 0.16 | Why? |
| Partial Thromboplastin Time | 1 | 2018 | 436 | 0.16 | Why? |
| Metabolome | 1 | 2021 | 624 | 0.16 | Why? |
| Quinazolinones | 1 | 2018 | 135 | 0.16 | Why? |
| Automation | 1 | 2019 | 429 | 0.16 | Why? |
| Automation, Laboratory | 1 | 2019 | 536 | 0.16 | Why? |
| Zebrafish | 1 | 2017 | 181 | 0.16 | Why? |
| Italy | 8 | 2021 | 38444 | 0.15 | Why? |
| Muscular Diseases | 1 | 2021 | 392 | 0.15 | Why? |
| Platelet Aggregation | 1 | 2018 | 318 | 0.15 | Why? |
| Phenotype | 4 | 2019 | 4037 | 0.15 | Why? |
| Predictive Value of Tests | 3 | 2020 | 9537 | 0.15 | Why? |
| Genotype | 4 | 2021 | 4697 | 0.15 | Why? |
| Diagnosis, Differential | 3 | 2018 | 7220 | 0.15 | Why? |
| Case-Control Studies | 5 | 2020 | 17671 | 0.14 | Why? |
| Hospitalization | 5 | 2021 | 54280 | 0.14 | Why? |
| Models, Economic | 1 | 2017 | 316 | 0.13 | Why? |
| Luminescent Measurements | 1 | 2019 | 924 | 0.13 | Why? |
| Gene Editing | 1 | 2017 | 330 | 0.13 | Why? |
| Hyponatremia | 1 | 2018 | 371 | 0.13 | Why? |
| Blood Component Transfusion | 1 | 2018 | 740 | 0.13 | Why? |
| Hypoglycemia | 1 | 2018 | 406 | 0.12 | Why? |
| Pneumonia, Viral | 9 | 2020 | 243684 | 0.12 | Why? |
| Protective Factors | 1 | 2019 | 1720 | 0.12 | Why? |
| Sequence Analysis, DNA | 2 | 2019 | 2830 | 0.12 | Why? |
| Coronavirus Infections | 9 | 2020 | 253789 | 0.12 | Why? |
| Linear Models | 1 | 2019 | 1914 | 0.12 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 1165 | 0.12 | Why? |
| Abdominal Pain | 1 | 2018 | 858 | 0.12 | Why? |
| Purines | 1 | 2018 | 816 | 0.12 | Why? |
| Heterozygote | 1 | 2012 | 249 | 0.11 | Why? |
| Prothrombin | 2 | 2017 | 149 | 0.11 | Why? |
| Disease Management | 2 | 2020 | 6841 | 0.11 | Why? |
| Pedigree | 1 | 2012 | 502 | 0.11 | Why? |
| Aged, 80 and over | 9 | 2021 | 88759 | 0.11 | Why? |
| Limit of Detection | 1 | 2019 | 2698 | 0.11 | Why? |
| Betacoronavirus | 9 | 2020 | 204454 | 0.11 | Why? |
| Administration, Oral | 1 | 2018 | 2340 | 0.11 | Why? |
| Up-Regulation | 1 | 2019 | 2249 | 0.11 | Why? |
| Venous Thromboembolism | 2 | 2021 | 4273 | 0.11 | Why? |
| Platelet Count | 2 | 2017 | 1381 | 0.11 | Why? |
| Thrombophilia | 2 | 2020 | 1935 | 0.10 | Why? |
| Young Adult | 7 | 2021 | 93724 | 0.10 | Why? |
| Colitis, Ulcerative | 1 | 2020 | 1037 | 0.10 | Why? |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2018 | 877 | 0.10 | Why? |
| Workflow | 1 | 2019 | 2373 | 0.10 | Why? |
| Rituximab | 1 | 2018 | 1096 | 0.10 | Why? |
| Methylprednisolone | 1 | 2020 | 2107 | 0.10 | Why? |
| Cohort Studies | 4 | 2021 | 36005 | 0.10 | Why? |
| Adolescent | 7 | 2019 | 86841 | 0.10 | Why? |
| Respiratory Insufficiency | 2 | 2020 | 7301 | 0.09 | Why? |
| Delayed Diagnosis | 1 | 2019 | 1529 | 0.09 | Why? |
| Fibrinolytic Agents | 1 | 2020 | 1702 | 0.09 | Why? |
| Recombinant Proteins | 1 | 2018 | 3786 | 0.09 | Why? |
| Frail Elderly | 1 | 2018 | 1427 | 0.09 | Why? |
| Europe | 2 | 2021 | 12702 | 0.09 | Why? |
| Treatment Outcome | 3 | 2019 | 51732 | 0.09 | Why? |
| Body Mass Index | 1 | 2021 | 4306 | 0.09 | Why? |
| Risk Factors | 8 | 2021 | 71621 | 0.08 | Why? |
| Acute Disease | 1 | 2020 | 6029 | 0.08 | Why? |
| Time Factors | 3 | 2019 | 31397 | 0.08 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2019 | 7868 | 0.08 | Why? |
| Intensive Care Units | 4 | 2020 | 29594 | 0.08 | Why? |
| High-Throughput Nucleotide Sequencing | 1 | 2018 | 3633 | 0.08 | Why? |
| Founder Effect | 1 | 2006 | 92 | 0.08 | Why? |
| Genetic Association Studies | 2 | 2021 | 559 | 0.08 | Why? |
| Frailty | 1 | 2018 | 1432 | 0.08 | Why? |
| Reproducibility of Results | 2 | 2019 | 11304 | 0.07 | Why? |
| Hepatitis C | 1 | 2017 | 1514 | 0.07 | Why? |
| Renin-Angiotensin System | 1 | 2021 | 3661 | 0.07 | Why? |
| Liver Cirrhosis | 1 | 2017 | 1810 | 0.07 | Why? |
| Genetic Variation | 1 | 2019 | 3919 | 0.07 | Why? |
| Severity of Illness Index | 4 | 2020 | 48226 | 0.07 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2021 | 3892 | 0.07 | Why? |
| Inpatients | 1 | 2020 | 5161 | 0.07 | Why? |
| Prospective Studies | 2 | 2021 | 43301 | 0.07 | Why? |
| Incidence | 3 | 2020 | 25622 | 0.07 | Why? |
| Blood Glucose | 1 | 2018 | 3642 | 0.06 | Why? |
| Molecular Sequence Data | 2 | 2015 | 3198 | 0.06 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2021 | 5277 | 0.06 | Why? |
| Point Mutation | 1 | 2006 | 481 | 0.06 | Why? |
| Antineoplastic Agents | 1 | 2018 | 3550 | 0.06 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.06 | Why? |
| Child, Preschool | 5 | 2017 | 36283 | 0.06 | Why? |
| Autoantibodies | 1 | 2012 | 2094 | 0.05 | Why? |
| Protein Folding | 1 | 2002 | 270 | 0.05 | Why? |
| Pneumonia | 1 | 2020 | 5652 | 0.05 | Why? |
| Chromosomes, Human, Pair 9 | 1 | 2020 | 196 | 0.05 | Why? |
| Prognosis | 2 | 2021 | 32490 | 0.05 | Why? |
| Mesalamine | 1 | 2020 | 89 | 0.05 | Why? |
| Models, Biological | 1 | 2017 | 4907 | 0.05 | Why? |
| Neural Conduction | 1 | 2021 | 261 | 0.05 | Why? |
| Electromyography | 1 | 2021 | 278 | 0.05 | Why? |
| Protein Conformation | 2 | 2019 | 4386 | 0.05 | Why? |
| Alternative Splicing | 1 | 2019 | 82 | 0.05 | Why? |
| Pandemics | 10 | 2021 | 389249 | 0.05 | Why? |
| Amino Acid Sequence | 2 | 2019 | 6049 | 0.05 | Why? |
| Genetic Loci | 1 | 2020 | 439 | 0.05 | Why? |
| Adenosine Diphosphate | 1 | 2018 | 63 | 0.04 | Why? |
| Cushing Syndrome | 1 | 2018 | 76 | 0.04 | Why? |
| Pregnancy | 1 | 2020 | 23879 | 0.04 | Why? |
| Risk Assessment | 2 | 2020 | 25439 | 0.04 | Why? |
| Diabetes Mellitus, Type 2 | 1 | 2018 | 6166 | 0.04 | Why? |
| Hep G2 Cells | 1 | 2017 | 391 | 0.04 | Why? |
| Protein C | 1 | 2017 | 141 | 0.04 | Why? |
| Cross-Sectional Studies | 2 | 2021 | 53120 | 0.04 | Why? |
| Respiratory Rate | 1 | 2020 | 691 | 0.04 | Why? |
| Anti-Bacterial Agents | 1 | 2018 | 10083 | 0.04 | Why? |
| Percutaneous Coronary Intervention | 1 | 2012 | 3646 | 0.04 | Why? |
| Lower Extremity | 1 | 2021 | 593 | 0.04 | Why? |
| Adenosine Triphosphate | 1 | 2018 | 294 | 0.04 | Why? |
| Sustained Virologic Response | 1 | 2017 | 378 | 0.04 | Why? |
| Depression | 1 | 2019 | 14116 | 0.04 | Why? |
| Patients' Rooms | 1 | 2019 | 675 | 0.03 | Why? |
| Base Sequence | 1 | 2002 | 3581 | 0.03 | Why? |
| RNA, Messenger | 2 | 2019 | 5131 | 0.03 | Why? |
| Return to Work | 1 | 2020 | 579 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.03 | Why? |
| Infant | 2 | 2016 | 30274 | 0.03 | Why? |
| Anxiety | 1 | 2019 | 17311 | 0.03 | Why? |
| False Negative Reactions | 1 | 2020 | 1785 | 0.03 | Why? |
| Tomography, X-Ray Computed | 1 | 2020 | 25144 | 0.03 | Why? |
| Protein Biosynthesis | 1 | 2017 | 653 | 0.03 | Why? |
| Genome-Wide Association Study | 1 | 2020 | 1648 | 0.03 | Why? |
| Costs and Cost Analysis | 1 | 2017 | 694 | 0.03 | Why? |
| Evolution, Molecular | 1 | 2006 | 3691 | 0.03 | Why? |
| Animals | 2 | 2018 | 78931 | 0.03 | Why? |
| Disease Progression | 2 | 2021 | 13580 | 0.03 | Why? |
| Ferritins | 1 | 2020 | 2055 | 0.03 | Why? |
| Area Under Curve | 1 | 2019 | 2564 | 0.03 | Why? |
| Early Diagnosis | 1 | 2020 | 2443 | 0.03 | Why? |
| Fatal Outcome | 1 | 2020 | 3438 | 0.03 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 1454 | 0.03 | Why? |
| Child | 4 | 2018 | 70012 | 0.02 | Why? |
| Cluster Analysis | 1 | 2017 | 3001 | 0.02 | Why? |
| Inflammation Mediators | 1 | 2020 | 2654 | 0.02 | Why? |
| Sensitivity and Specificity | 2 | 2020 | 22971 | 0.02 | Why? |
| Risk | 1 | 2021 | 5288 | 0.02 | Why? |
| Antiviral Agents | 2 | 2020 | 41703 | 0.02 | Why? |
| Leukocyte Count | 1 | 2017 | 3178 | 0.02 | Why? |
| Prevalence | 2 | 2021 | 25773 | 0.02 | Why? |
| Hepacivirus | 1 | 2017 | 1509 | 0.02 | Why? |
| Heparin | 1 | 2020 | 2600 | 0.02 | Why? |
| Drug Therapy, Combination | 1 | 2020 | 7268 | 0.02 | Why? |
| Oxygen | 1 | 2020 | 3715 | 0.02 | Why? |
| ROC Curve | 1 | 2019 | 6024 | 0.02 | Why? |
| Gene Expression Regulation | 1 | 2019 | 4020 | 0.02 | Why? |
| Lymphocyte Count | 1 | 2017 | 4758 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.02 | Why? |
| Homozygote | 1 | 2006 | 230 | 0.02 | Why? |
| Health Status | 1 | 2018 | 3259 | 0.02 | Why? |
| Turkey | 1 | 2015 | 3937 | 0.02 | Why? |
| Models, Molecular | 1 | 2019 | 7616 | 0.02 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.02 | Why? |
| Proportional Hazards Models | 1 | 2016 | 6543 | 0.02 | Why? |
| HEK293 Cells | 1 | 2017 | 8394 | 0.02 | Why? |
| C-Reactive Protein | 1 | 2020 | 7972 | 0.02 | Why? |
| Survival Analysis | 1 | 2017 | 7592 | 0.02 | Why? |
| Computational Biology | 1 | 2019 | 4514 | 0.02 | Why? |
| Cell Line | 1 | 2019 | 12040 | 0.02 | Why? |
| Interleukin-6 | 1 | 2020 | 7522 | 0.01 | Why? |
| Spain | 1 | 2020 | 15545 | 0.01 | Why? |
| Hospitals | 1 | 2021 | 11793 | 0.01 | Why? |
| Neutrophils | 1 | 2017 | 5476 | 0.01 | Why? |
| Viral Load | 1 | 2021 | 15850 | 0.01 | Why? |
| Host-Pathogen Interactions | 1 | 2020 | 11041 | 0.01 | Why? |
| Retrospective Studies | 2 | 2021 | 105322 | 0.01 | Why? |
| Obesity | 1 | 2018 | 7388 | 0.01 | Why? |
| Mice | 1 | 2017 | 21357 | 0.01 | Why? |
| Age Factors | 1 | 2018 | 21039 | 0.01 | Why? |
| Comorbidity | 1 | 2021 | 34796 | 0.01 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.01 | Why? |
| Public Health | 1 | 2021 | 16359 | 0.01 | Why? |
| Software | 1 | 2006 | 2501 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2021 | 43792 | 0.01 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.01 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.01 | Why? |
| Lung | 1 | 2021 | 31049 | 0.01 | Why? |